A Phase 2 randomized controlled trial (RCT) examining its impact on cognitive dysfunction in individuals with Major Depressive Disorder (MDD) reported no significant improvement in the primary outcome of executive functioning
Important questions include Whether long term use is anticipated What is known about discontinuation How maintenance is approached if therapy changes Follow up analyses from randomized controlled trials show that discontinuing GLP 1 therapy is commonly associated with a return toward baseline weight or metabolic set point
Frage von Torben C
A supplier that cannot produce testing documentation, hides its sourcing, or leans on splashy therapeutic claims is telling you something about how it operates
[1] Semaglutide benefits from extensive clinical experience, long-term safety data, and full regulatory approval, whereas Retatrutide remains investigational, with only Phase 2 data
Bunting, T., Filion, P., Hoernig, H., Seasons, M., & Lederer, J
